Innovo Bioanalysis
Provides contract bioanalytical research services and develops mass spectrometry–based bioanalytical methodology to identify biomarkers, characterize metabolites, and support DMPK/PK/PD/TK and safety assessments for drug discovery and development. Engages in collaborative research with academic and industry partners and publishes methods for cross-species metabolite and biomarker analysis.
Industries
Nr. of Employees
small (1-50)
Innovo Bioanalysis
Mansfield, Massachusetts, United States, North America
Products
Bioanalytical Research Services
Bioanalysis of biomarkers, drugs, and metabolites in biological samples to address pharmacokinetics (PK), pharmacodynamics (PD), drug metabolism (DM), and toxicokinetics (TK) in drug discovery and development.
Target Tissue Analysis
Target tissue analysis services covering tissues such as brain, liver, kidney, tumor, heart, bone, and ocular tissues using LC/MS/MS technologies.
Bioanalytical Method Development
Custom bioanalytical method development services using LC/MS/MS technologies to support drug discovery and development.
Biomarker Analysis
Biomarker analysis in biological fluids and target tissues, including in vivo and in vitro assays for transporters, CYP, and pharmacological biomarkers.
Pharmacokinetic (PK) Analysis
Pharmacokinetic analysis in biological fluids such as plasma, blood, CSF, and urine to address DMPK and PK/PD requirements.
Toxicokinetic (TK) Analysis and MIST Coverage Assessments
Toxicokinetic analysis and Metabolite in Safety Testing (MIST) coverage assessments using advanced LC/MS/MS workflows.
Bioanalytical Research Services
Bioanalysis of biomarkers, drugs, and metabolites in biological samples to address pharmacokinetics (PK), pharmacodynamics (PD), drug metabolism (DM), and toxicokinetics (TK) in drug discovery and development.
Target Tissue Analysis
Target tissue analysis services covering tissues such as brain, liver, kidney, tumor, heart, bone, and ocular tissues using LC/MS/MS technologies.
Bioanalytical Method Development
Custom bioanalytical method development services using LC/MS/MS technologies to support drug discovery and development.
Biomarker Analysis
Biomarker analysis in biological fluids and target tissues, including in vivo and in vitro assays for transporters, CYP, and pharmacological biomarkers.
Pharmacokinetic (PK) Analysis
Pharmacokinetic analysis in biological fluids such as plasma, blood, CSF, and urine to address DMPK and PK/PD requirements.
Toxicokinetic (TK) Analysis and MIST Coverage Assessments
Toxicokinetic analysis and Metabolite in Safety Testing (MIST) coverage assessments using advanced LC/MS/MS workflows.
Services
Design and execution of bioanalysis for drugs, metabolites, and biomarkers to support DMPK, PK/PD and safety assessments.
Analytical measurement of biomarkers in biological fluids and a variety of target tissues for translational research and drug development.
Design and execution of bioanalysis for drugs, metabolites, and biomarkers to support DMPK, PK/PD and safety assessments.
Analytical measurement of biomarkers in biological fluids and a variety of target tissues for translational research and drug development.
Expertise Areas
- Mass spectrometry–based bioanalysis
- Bioanalytical method development
- Biomarker discovery and quantitation
- DMPK / PK / PD analysis
Key Technologies
- Mass spectrometry
- Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
- Ultra-high-performance liquid chromatography with high-resolution MS (UHPLC–HRMS)
- Untargeted metabolomics / unbiased scanning
News & Updates
Company leadership chaired a session on discovery bioanalysis and new technologies at the 14th Annual Applied Pharmaceutical Analysis Meeting.
Company leadership presented at a symposium focused on contributions of women scientists to drug metabolism, drug transporter, and pharmacokinetics research.
Publication describing IVIVE approaches for transporter-mediated drug–drug interactions.
Study reporting potential novel biomarkers identified via metabolite profiling in dosed animals.
Method publication on untargeted UHPLC–HRMS scanning and data-banking for cross-study metabolite comparison.
Company leadership chaired a session on discovery bioanalysis and new technologies at the 14th Annual Applied Pharmaceutical Analysis Meeting.
Company leadership presented at a symposium focused on contributions of women scientists to drug metabolism, drug transporter, and pharmacokinetics research.
Publication describing IVIVE approaches for transporter-mediated drug–drug interactions.
Study reporting potential novel biomarkers identified via metabolite profiling in dosed animals.
Method publication on untargeted UHPLC–HRMS scanning and data-banking for cross-study metabolite comparison.